News
By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...
2d
MedPage Today on MSNFirst-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast CancerCHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...
US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a ...
The latest findings support the expectation that the combination therapy will become the new SOC in PD-L1-positive TNBC.
Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...
Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...
1d
Clinical Trials Arena on MSNASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumblesAdditional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is ...
1don MSN
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results